Literature DB >> 26928186

Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study.

B A Perry1, K R Archer2,3, Y Song4, Y Ma5, J K Green5,6,7, F Elefteriou1,8,7, K M Dahir1.   

Abstract

UNLABELLED: The impact of pharmacotherapy for attention deficit/hyperactivity disorder on fracture risk has not been well studied. In this retrospective cohort study, medication therapy was associated with lower fracture incidence. Further studies are needed to better characterize the short-term and long-term effects of these medications on bone health and fracture risk.
INTRODUCTION: Attention deficit/hyperactivity disorder (ADHD) is associated with increased risk of bone fractures. The impact of pharmacotherapy with either stimulant or non-stimulant medications on fracture risk has not been well characterized. We performed a study to compare fracture incidence in ADHD patients treated with stimulant or non-stimulant medications vs. no pharmacotherapy.
METHODS: In this retrospective cohort study, data were extracted from a large electronic medical record. A total of 10,066 subjects with ADHD, 40 years or younger, were included. We extracted data regarding stimulant and non-stimulant ADHD medications, corticosteroids, fracture data, demographic data, and diabetes history.
RESULTS: A total of 1015 patients (10 %) sustained fractures. Multivariable Cox proportional hazard analysis indicated that compared to those with two or more prescriptions for an ADHD medication, individuals without documented medication therapy had a significantly increased hazard of fracture (hazard ratio [HR] 3.9, 95 % confidence interval [CI] 2.6-5.9). However, the hazard ratio for stimulant vs. non-stimulant medication (HR 0.92, 95 % CI 0.60-1.4) was not statistically significant.
CONCLUSIONS: Three times as many patients with no documented ADHD medication prescriptions suffer a fracture compared to patients with a history of two or more prescriptions for an ADHD medication. Treatment and adherence are thus important to prevent fracture in this population.

Entities:  

Keywords:  ADHD; Attention; Bone; Fracture; Hyperactivity

Mesh:

Substances:

Year:  2016        PMID: 26928186     DOI: 10.1007/s00198-016-3547-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  22 in total

Review 1.  Bone quality: getting closer to a definition.

Authors:  Nelson B Watts
Journal:  J Bone Miner Res       Date:  2002-07       Impact factor: 6.741

2.  ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Mark Wolraich; Lawrence Brown; Ronald T Brown; George DuPaul; Marian Earls; Heidi M Feldman; Theodore G Ganiats; Beth Kaplanek; Bruce Meyer; James Perrin; Karen Pierce; Michael Reiff; Martin T Stein; Susanna Visser
Journal:  Pediatrics       Date:  2011-10-16       Impact factor: 7.124

3.  MedEx: a medication information extraction system for clinical narratives.

Authors:  Hua Xu; Shane P Stenner; Son Doan; Kevin B Johnson; Lemuel R Waitman; Joshua C Denny
Journal:  J Am Med Inform Assoc       Date:  2010 Jan-Feb       Impact factor: 4.497

4.  Attention-deficit-hyperactivity disorder increases risk of bone fracture: a population-based cohort study.

Authors:  I-Ching Chou; Che-Chen Lin; Fung-Chang Sung; Chia-Hung Kao
Journal:  Dev Med Child Neurol       Date:  2014-05-28       Impact factor: 5.449

5.  Effects of long-term psychostimulant medication on growth of children with ADHD.

Authors:  Ditza A Zachor; Alicia W Roberts; J Bart Hodgens; Janet S Isaacs; Joav Merrick
Journal:  Res Dev Disabil       Date:  2005-06-13

6.  Extracellular norepinephrine clearance by the norepinephrine transporter is required for skeletal homeostasis.

Authors:  Yun Ma; Jessica J Krueger; Sara N Redmon; Sasidhar Uppuganti; Jeffry S Nyman; Maureen K Hahn; Florent Elefteriou
Journal:  J Biol Chem       Date:  2013-09-04       Impact factor: 5.157

7.  Bone mineral density and turnover in children with attention-deficit hyperactivity disorder receiving methylphenidate.

Authors:  E Lahat; M Weiss; A Ben-Shlomo; S Evans; T Bistritzer
Journal:  J Child Neurol       Date:  2000-07       Impact factor: 1.987

8.  Fracture patterns in children. Analysis of 8,682 fractures with special reference to incidence, etiology and secular changes in a Swedish urban population 1950-1979.

Authors:  L A Landin
Journal:  Acta Orthop Scand Suppl       Date:  1983

9.  Attention deficit hyperactivity disorder and increased risk of injury.

Authors:  R M Merrill; J L Lyon; R K Baker; L H Gren
Journal:  Adv Med Sci       Date:  2009       Impact factor: 3.287

10.  Vigorous physical activity increases fracture risk in children irrespective of bone mass: a prospective study of the independent risk factors for fractures in healthy children.

Authors:  Emma M Clark; Andy R Ness; Jon H Tobias
Journal:  J Bone Miner Res       Date:  2008-07       Impact factor: 6.741

View more
  4 in total

Review 1.  The Impact of Psychotropic Medications on Bone Health in Youth.

Authors:  Jessie N Rice; Carrie B Gillett; Nasuh M Malas
Journal:  Curr Psychiatry Rep       Date:  2018-09-24       Impact factor: 5.285

Review 2.  Impact of the Autonomic Nervous System on the Skeleton.

Authors:  Florent Elefteriou
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

3.  Impact of attention deficit hyperactivity disorder therapy on fracture risk in children treated in German pediatric practices.

Authors:  L Jacob; K Kostev
Journal:  Osteoporos Int       Date:  2016-11-24       Impact factor: 4.507

4.  The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan.

Authors:  Vincent Chin-Hung Chen; Yao-Hsu Yang; Yin-To Liao; Ting-Yu Kuo; Hsin-Yi Liang; Kuo-You Huang; Yin-Cheng Huang; Yena Lee; Roger S McIntyre; Tzu-Chin Lin
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.